Moderna

Bird flu cases rose to 64 this year, with detections in wastewater and signs of dangerous mutations. Experts warn of potential pandemic risk as the virus spreads among animals and humans, with some cases lacking identified sources of infection.

Moderna's share price has fluctuated, but its mRNA technology has significant growth potential in treating diseases like cancer and rare conditions. Despite challenges, mRNA's versatility in immunology and regenerative medicine offers transformative possibilities, though regulatory and ethical concerns persist.

NH Life Sciences, a statewide trade group, added new members, reaching 23, including Resonetics, BA Sciences, Ovik Health, and associate members like Decco and Ethikos Tech. The group aims to guide New Hampshire’s life sciences growth.

mRNA technology proved effective during COVID-19, paving the way for broader applications in diagnostics, therapeutics, and personalized medicine. Its advantages include speed, scalability, safety, and versatility across diseases like cancer and autoimmune conditions. The UK, with its strong research institutions and industry presence, is well-positioned to lead in mRNA development, but needs strategic investment in clinical trials, manufacturing, regulation, and infrastructure to realize its potential.

Academia Sinica in Taiwan leads interdisciplinary research in biotech, pharmaceuticals, and medical science through advanced facilities like RNA Technology Platform, Taiwan Mouse Clinic, BioTReC Nucleic Acid Pilot Plant, and Taiwan Biobank, fostering global healthcare advancements.

FDA agrees that ongoing Phase 1/2 trials of AMT-130, compared with an external control group, may support accelerated approval for Huntington’s disease. Key measures include changes in cUHDRS and NfL levels. Accelerated approval pathway aims to speed delivery of potentially life-changing therapy, reducing time to potential licensure by approximately five years.

Moderna faces challenges with a 60% drop in share value year-to-date. Despite $4 billion R&D cuts by 2028, investors predict losses. Moderna's market cap dropped to $17 billion from $181 billion in 2021. Despite positive news, stock prices continued to decline. Moderna plans to launch 10 products by 2027, cutting $1.1 billion from the annual budget. FDA detected severe side effects in Moderna's RSV vaccine trials. Moderna's stock fell over 8% due to Robert F. Kennedy Jr.'s nomination to head HHS. Jefferies analysts anticipate Phase III data for Moderna's cytomegalovirus vaccine could impact stock movement.

Merck's clesrovimab, awaiting FDA approval by June 2025, aims to protect newborns from RSV, competing with Sanofi and AstraZeneca's Beyfortus. RSV vaccines for young children are on hold due to safety concerns. Merck's clesrovimab could be available for ordering by July if approved.

© 2024 www.detroitnews.com

Orly Vardeny discussed FINEARTS-HF trial findings on finerenone's efficacy in HF patients with EF ≥40%, reducing cardiovascular death and HF events. Finerenone shows kidney-protective effects and lower hyperkalemia risk than steroidal MRAs, though hyperkalemia incidence doubled. The trial supports finerenone's use alongside SGLT2 inhibitors, addressing HF treatment needs, with improvements in patient-reported functional status. Challenges remain in translating trial findings into clinical practice.